

Attorney Docket No.: 47234-0003-00US
 Application No. 10/500,841
 Reply to Office Action Dated: April 11, 2007
 Amendment Dated: October 31, 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5. (Canceled)

6. (Currently amended) A pharmaceutical composition comprising an amount of the polypeptide fragment of claim 25 sufficient to accelerate neovascularization~~accelerator comprising the peptide or protein according to Claim 1,~~ and a pharmaceutically acceptable carrier.

7. (Currently amended) A wound healing agent comprising a pharmaceutically effective amount of the ~~peptide or protein~~ polypeptide fragment of claim ~~[[1]]~~ 25 and a pharmaceutically acceptable carrier.

Claims 8-22. (Canceled)

23. (Withdrawn, currently amended) A method for accelerating neovascularization comprising administering an effective amount of the ~~peptide or the protein~~ polypeptide fragment of claim ~~[[1]]~~ 25 and a pharmaceutically acceptable carrier therefor to a mammal.

24. (Currently amended) An agent for ~~preventing and/or~~ treating arteriosclerosis containing a pharmaceutically effective amount of the ~~peptide or protein as defined in Claim 1~~ polypeptide fragment of claim 25 and a pharmaceutically acceptable carrier therefor.

25. (New) A polypeptide fragment of an N-acetylglucosaminyltransferase V (GnT-V), comprising a basic amino acid cluster region,
 wherein the basic amino acid cluster region comprises the amino acid sequence of SEQ ID NO: 7 and up to 50 contiguous amino acids encoded by the sequence shown in SEQ ID NO: 6, or a variant thereof,
 wherein the polypeptide fragment or variant thereof possesses neovascularization activity,

Attorney Docket No.: 47234-0003-00US
Application No. 10/500,841
Reply to Office Action Dated: April 11, 2007
Amendment Dated: October 31, 2007

wherein the number of amino acids modified by addition, removal, or substitution in the variant is up to 10% of the number of amino acids in the basic amino acid cluster region, and

wherein the addition, removal, or substitution is conducted on amino acids other than basic amino acids.

26. (New) The polypeptide of claim 25, wherein one amino acid other than a basic amino acid of the variant is added, removed, or substituted from the amino acid sequence encoded by the sequence shown in SEQ ID NO: 6.

27. (New) The polypeptide of claim 25, wherein the number of basic amino acids accounts for greater than 30% of the total number of amino acids in said fragment.

28. (New) The polypeptide of claim 25, consisting of the amino acid sequence shown in SEQ ID NO: 11.

29. (New) The polypeptide of claim 25, consisting of the amino acid sequence shown in SEQ ID NO: 7.

30. (New) A pharmaceutical composition comprising a pharmaceutically effective amount of a polypeptide consisting of SEQ ID NO: 11 or a polypeptide consisting of SEQ ID NO: 7.